HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Hansoh Pharmaceutical Group Company Limited

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:09:09 2024-04-25 am EDT			5-day change	1st Jan Change
16.8 ^HKD	0.00%		+7.28%	+6.60%

Apr. 03	Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug	MT
Apr. 03	Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer	CI

Blossom Bioscience, Ltd. announced that it has received $72 million in funding from Cormorant Asset Management, LLC, Hansoh Pharmaceutical Group Company Limited

June 15, 2021

Blossom BioScience announced that it has received $72,000,000 in its series A round of funding co-led by new investors, Cormorant Asset Management, LLC and Hansoh Pharmaceutical Group Company Limited (SEHK:3692) on June 16, 2021.

Latest news about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug	Apr. 03	MT
Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer	Apr. 03	CI
Hansoh Pharmaceutical Group Company Limited Recommends Final Dividend, Payable on July 17, 2024	Mar. 26	CI
Hansoh Pharmaceutical Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Nomura Downgrades Hansoh Pharmaceutical to Neutral From Buy, Adjusts Price Target to HK$15.03 From HK$13.01	Mar. 14	MT
Hansoh Pharmaceutical Gets Nod to Trial Nephropathy Treatment Capsules	Feb. 08	MT
Hansoh Pharmaceutical Buys Back 3 Million Shares	Jan. 31	MT
Fed, China Property Outlooks Roil Asian Stock Markets	Jan. 30	MT
Hansoh Secures Chinese Nod For Clinical Trial Of Anti-Diabetes Drug	Jan. 23	MT
China Outlook, Tech Rally Roils Asian Stock Markets	Jan. 19	MT
Hansoh Pharmaceutical Units Gets Clinical Trial Notice in China for Schizophrenia Treatment	Jan. 17	MT
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets	Jan. 17	CI
Federal Reserve Outlook Mutes Asian Stock Markets	Jan. 05	MT
Hansoh Pharmaceutical’s Trustee Buys Back Shares	Jan. 02	MT
GSK plc Enters Exclusive License Agreement with Hansoh for HS-20093	Dec. 20	CI
GSK Enters Exclusive License Agreement With Hansoh for HS-20093 Cancer Antibody	Dec. 20	DJ
Hansoh Pharmaceutical Grants GSK Subsidiary Marketing License for Tumor Drug HS-20093	Dec. 20	MT
Games Workshop seals Amazon deal for Warhammer 40,000	Dec. 18	AN
GSK looks for deals in China as rebuilds relationship	Dec. 17	AN
Hansoh Pharma's Three Drugs Added to China’s National Reimbursement Drug List	Dec. 14	MT
China OKs Clinical Trial for Hansoh Pharmaceutical Units' Hypertrophic Cardiomyopathy Treatment	Nov. 12	MT
Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice	Nov. 10	CI
China Grants Drug Registration Approval for Hansoh Pharma Unit's Skin Infection Treatment	Nov. 02	MT
Hansoh Pharmaceutical Grants GSK Subsidiary International Marketing License for HS-20089	23-10-23	MT
Hansoh Pharmaceutical Gets Nod to Test HS-20106 Injections	23-10-20	MT

Chart Hansoh Pharmaceutical Group Company Limited

Duration

Period

Chart Hansoh Pharmaceutical Group Company Limited

More charts

Company Profile

Hansoh Pharmaceutical Group Company Limited specializes in the development, manufacture and marketing of pharmaceutical products for the treatment of tumor, infectious, metabolic and autoimmune diseases. Net sales break down by revenue source as follows: - sales of pharmaceutical products (99.1%); - sales of research and development services (0.9%).

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for Hansoh Pharmaceutical Group Company Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.54 CNY

Average target price

17.47 CNY

Spread / Average Target

+12.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED	+6.60%	12.7B
NOVO NORDISK A/S	+24.08%	562B
JOHNSON & JOHNSON	-6.45%	358B
MERCK & CO., INC.	+18.54%	322B
ABBVIE INC.	+7.32%	297B
ASTRAZENECA PLC	+12.89%	219B
NOVARTIS AG	+5.81%	199B
ROCHE HOLDING AG	-10.35%	196B
PFIZER, INC.	-10.82%	149B
AMGEN INC.	-6.71%	146B

Other Pharmaceuticals

Hansoh Pharmaceutical Group Company Limited

Equities

3692

KYG549581067

Pharmaceuticals

Blossom Bioscience, Ltd. announced that it has received $72 million in funding from Cormorant Asset Management, LLC, Hansoh Pharmaceutical Group Company Limited

Latest news about Hansoh Pharmaceutical Group Company Limited

Chart Hansoh Pharmaceutical Group Company Limited

Company Profile

Income Statement Evolution

Ratings for Hansoh Pharmaceutical Group Company Limited

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals